Genzum Receives up to $20M Investment from SG

Genzum, a Los Angeles, CA-based pharmaceutical company focused on the development, commercialization and out licensing of niche ANDA (generic) pharmaceutical products, received an up to $20m investment from SG‘s Alternative Investments Division.

In conjunction with the transaction, Dovi Frances, President of SG, will join Genzum’s board.

The growth capital will allow the company to expand their pipeline of generic pharmaceutical products.

Led by CEO Chris Achar, COO Rajin Ahuja, and CSO Dr. Nehru Gaddipati, Genzum is a Generic Pharmaceutical Product Development and Out-licensing company. It uses an ecosystem of facilities and expert pharmaceutical development and clinical trials capabilities to operate throughout the pharmaceutical development cycle from product selection and formulation to clinical trials and FDA approval.
The company has offices in New York, Chicago and India.

FinSMEs

23/06/2014

Join the discussion